Article History
Accepted: 27 November 2023
First Online: 3 January 2024
Competing interests
: A.J.N. declares research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company and Novartis Pharmaceuticals and consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company and Novartis. N.J.P. declares research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Duke Clinical Research Institute, Eli Lilly & Company, Novartis Pharmaceuticals, Novo Nordisk Pharmaceutical Company and Verily Sciences Research Company and consulting fees from AstraZeneca, Boehringer Ingelheim, CRISPR Therapeutics, Eli Lilly & Company, Merck, Novo Nordisk Pharmaceutical Company and Novartis. H.B.B. declares research grants from BeBetter Therapeutics, Boehringer Ingelheim, the Elton John AIDS Foundation, the Hilton Foundation, Improved Patient Outcomes, Merck, NHLBI, Novo Nordisk, Otsuka, Pfizer, Sanofi and Veterans Affairs and consulting fees from Abbott, Imatar, Novartis, Sanofi, Vidya, Walmart and Webmed. H.B.B. is on the Board of Directors of Preventric Diagnostics.